BioLife Solutions Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

BioLife Solutions (Nasdaq: BLFS) announced its Q2 2024 financial results, highlighting an 11% sequential increase in Cell Processing revenue to $18 million. Total revenue for Q2 was $28.3 million, a 3% decrease year-over-year but a 6% sequential increase. The GAAP gross margin improved to 51%, while non-GAAP adjusted gross margin was 52%. The company experienced a GAAP net loss of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million, or 17%.

BioLife revised its full-year 2024 revenue guidance to between $99 million and $101 million and increased Cell Processing revenue guidance to $70 million to $71 million. The company also noted a $4.1 million write-off related to its iVexSol equity investment.

Additional business highlights include 12 new FDA Master File cross-references and the launch of the CellSeal CryoCase. The sale of the GCI freezer division was completed in April, and its financials have been excluded.

Positive

• Sequential Cell Processing revenue increased by 11% to $18 million.
• GAAP gross margin improved to 51%; non-GAAP adjusted gross margin at 52%.
• Non-GAAP adjusted EBITDA for Q2 2024 was $4.8 million, 17% of revenue.
• Raised full-year 2024 revenue guidance to $99 million to $101 million.
• Reduced operating loss from continuing operations for six months to $7 million, compared to $19.3 million in 2023.

Negative

• Total revenue decreased by 3% year-over-year.
• GAAP net loss from continuing operations was $7.1 million in Q2 2024.
• Loss per share from continuing operations increased to $0.16 from $0.12.

Insights

Financial Analyst

BioLife Solutions' Q2 2024 results show mixed signals. Revenue decreased 3% YoY to $28.3 million, but increased 6% sequentially. The Cell Processing segment, their core business, grew 11% sequentially to $18 million, indicating improving momentum.

Notably, GAAP gross margin expanded significantly to 51% from 35% last year, reflecting improved operational efficiency. The company also reported positive adjusted EBITDA of $4.8 million (17% of revenue), a substantial improvement from $1.7 million last year.

BioLife raised its full-year 2024 revenue guidance to $99-101 million, with Cell Processing expected to grow 25-26% in H2 2024. This upward revision, coupled with margin improvements, suggests a positive outlook for the company's core business.

Medical Research Analyst

BioLife's strategic focus on cell and gene therapy (CGT) appears to be paying off. The company reports its biopreservation media is used in 70% of U.S. commercial CGT trials, demonstrating strong market penetration. Moreover, it's embedded in 15 unique commercial CGTs, with 9 additional approvals or expansions expected in the next 12 months.

The introduction of the CellSeal® CryoCase™ shows BioLife's commitment to innovation in CGT primary packaging. This product development, coupled with the company's strong presence in FDA Master File cross-references (728 cumulative), indicates a robust position in the growing CGT market.

The favorable regulatory environment, including increased therapy approvals and broadened indications, bodes well for BioLife's future growth prospects in this specialized field.

Cell Processing revenue increased 11% sequentially to $18.0 million

GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52%

GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17%

Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million

Conference call begins at 4:30 p.m. Eastern time today

BOTHELL, Wash., Aug. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended June 30, 2024 and updated revenue guidance for 2024.

"We are pleased with our second quarter results. The business has stabilized and momentum continues with our third consecutive quarter of sequential revenue growth. With our continued focus on streamlining the business, we are now beginning to benefit from the strength of our high margin, recurring and consumable product offerings," said Roderick de Greef, Chairman and CEO. "Our focus on our core cell processing product platform is emerging in our financial performance, with notable expansions in gross margin, increased adjusted EBITDA, and encouraging momentum into the second half of the year."

de Greef continued, "As a pure play enabler of CGT's globally, we are strategically aligned with the favorable secular trends, including a more favorable regulatory environment evidenced by increased therapy approvals with broadened indications, expanding geographic regions, and forward movement in the lines of treatment. We believe our market-leading biopreservation franchise supports more than 70% of U.S. commercial CGT trials and sets us up for a sustainable long-term and a promising future."

Second Quarter 2024 Business Highlights

• Processed 12 new U.S. FDA Master File cross references for our biopreservation media, bringing the cumulative total processed to 728.
• Our biopreservation media is embedded in 15 unique commercial CGTs as of June 30, 2024, with an expectation that 9 additional product approvals, geographic expansions, or new indications will occur in the next 12 months.
• In May, we introduced the CellSeal^® CryoCase^TM at the International Society for Cell & Gene Therapies (ISCT) conference. The CryoCase is an addition to our CellSeal product line and was developed for the needs of CGT primary packaging to replace cryopreservation bags.
• In April, we completed the sale of our GCI freezer division, and the financial information presented in this news release excludes the results of GCI from the consolidated financial results.

Second Quarter 2024 Financial Performance

BioLife Solutions is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife Solutions is presenting adjusted (non-GAAP) metrics on a consolidated basis and also presenting its non-GAAP financial metrics excluding the financial results of GCI from its consolidated results. Reconciliations of GAAP to non-GAAP metrics appear at the end of this news release.

On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Global Cooling"), to GCI Holdings Company, LLC, an Ohio limited liability company ("GCI Holdings") pursuant to a Stock Purchase Agreement (the "Purchase Agreement"), by and between the Company and GCI Holdings (the "Global Cooling Divestiture"). Upon the execution of the Purchase Agreement, on April 17, 2024, Global Cooling business is presented in the accompanying unaudited condensed financial statements as a discontinued operation for all periods presented. All amounts included in this earnings release relate to continuing operations unless otherwise noted.

REVENUE

• Total revenue for the second quarter of 2024 was $28.3 million, a decrease of $0.9 million, or 3%, from $29.2 million for the second quarter of 2023 and up $1.5 million, or 6%, sequentially from the first quarter of 2024.
  • Cell Processing platform revenue was $18.0 million, a decrease of $0.7 million, or 4%, from the same period in 2023 and up $1.8 million, or 11%, sequentially from the first quarter of 2024.
  • Biostorage Services platform revenue was $7.0 million, an increase of $5,000, from the same period in 2023 and down $0.1 million, or 2%, sequentially from the first quarter of 2024.
  • Freezers and Thaw Systems platform revenue was $3.4 million, a decrease of $0.2 million, or 7%, from the same period in 2023 and down $0.1 million, or 4%, sequentially from the first quarter of 2024.
• Total revenue for the six months ended June 30, 2024 was $55.1 million, a decrease of $3.3 million, or 6%, from the same period in 2023.
  • Cell Processing platform revenue for the six months ended June 30, 2024 was $34.2 million, a decrease of $3.5 million, or 9%, from the same period in 2023.
  • Biostorage Services platform revenue was $14.0 million, an increase of $1.4 million, or 11%, from the same period in 2023 .
  • Freezers and Thaw Systems platform revenue was $6.9 million, a decrease of $1.2 million, or 15%, from the same period in 2023.

GROSS MARGIN

• Gross margin (GAAP) for the second quarter of 2024 was 51% compared with 35% for the second quarter of 2023. Adjusted gross margin (non-GAAP) for the second quarter of 2024 was 52% compared with 45% for the second quarter of 2023.
• Gross margin (GAAP) for the six months ended June 30, 2024 was 51% compared with 40% for the same period in 2023. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2024 was 53% compared with 47% for the same period in 2023.

OPERATING LOSS FROM CONTINUING OPERATIONS

• Operating loss from continuing operations (GAAP) for the second quarter of 2024 was $2.8 million compared with $10.6 million for the second quarter of 2023. Adjusted operating loss from continuing operations (non-GAAP) for the second quarter of 2024 was $2.1 million compared with $5.8 million for the second quarter of 2023.
• Operating loss from continuing operations (GAAP) for the six months ended June 30, 2024 was $7.0 million compared with $19.3 million for the same period in 2023. Adjusted operating loss from continuing operations (non-GAAP) for the six months ended June 30, 2024 was $5.1 million compared with $11.4 million for the same period in 2023.

NET LOSS FROM CONTINUING OPERATIONS

• Net loss from continuing operations (GAAP) for the second quarter of 2024 was $7.1 million, which includes a $4.1 million write-off of our iVexSol equity investment, compared with $5.5 million for the second quarter of 2023. Adjusted net loss from continuing operations (non-GAAP) for the second quarter of 2024 was $2.3 million compared with $5.8 million for the second quarter of 2023.
• Net loss from continuing operations (GAAP) for the six months ended June 30, 2024 was $11.4 million, which includes a $4.1 million write-off of our iVexSol equity investment, compared with $14.2 million for the same period in 2023. Adjusted net loss from continuing operations (non-GAAP) for the six months ended June 30, 2024 was $5.3 million compared with $11.4 million for the same period in 2023.

LOSS PER SHARE FROM CONTINUING OPERATIONS

• Loss per share from continuing operations (GAAP) for the second quarter of 2024 was $0.16 compared with $0.12 for the second quarter of 2023.
• Loss per share from continuing operations (GAAP) for the six months ended June 30, 2024 was $0.25 compared with $0.33 for the same period in 2023.

ADJUSTED EBITDA

• Adjusted EBITDA, a non-GAAP measure, for the second quarter of 2024 was $4.8 million, or 17% of revenue, compared with $1.7 million, or 6% of revenue, for the second quarter of 2023.
• Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2024 was $8.5 million, or 15% of revenue, compared with $5.4 million, or 9% of revenue, for the same period in 2023.

CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES

• Cash, cash equivalents, and marketable securities as of June 30, 2024, were $36.9 million.

(As a result of showing amounts in millions, rounding difference may exist in the percentages above.)

2024 Revenue Guidance

BioLife Solutions is updating its 2024 revenue guidance to $99.0 million to $101.0 million from prior guidance of $95.5 million to $100.0 million. This guidance is based on expectations for BioLife's Cell Processing and Biostorage Services platforms, which now include results from its ThawSTAR^® product line and do not include revenue from the freezer product line (GCI and CBS).

• Cell Processing platform revenue: Revised to $70.0 million to $71.0 million from prior guidance of $66.0 million to $68.5 million. The revised guidance represents an increase of 6% to 8% compared with 2023. Compared with annualizing the second half of 2023 revenue run rate, growth is expected to be 25% to 26%
• Biostorage Services platform revenue: Revised to $29.0 million to $30.0 million from prior guidance of $29.5 million to $31.5 million. The revised guidance represents an increase of 3% to 7% compared with 2023. This platform now includes the ThawSTAR automated thawing product line. Without ThawSTAR, the growth rate is expected to be 8% to 12%.

Management expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024.

Conference Call & Webcast

Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 877-346-6112 or 848-280-6350 for international callers. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com/ for 90 days.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, storage and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. In addition to the non-GAAP measures included within this release on a consolidated basis, we also included non-GAAP measures excluding the operations of Global Cooling. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release.

We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information.

While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Media & Investor Relations

At the Company

Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors

LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com

On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Global Cooling"), to GCI Holdings Company, LLC, an Ohio limited liability company ("GCI Holdings") pursuant to a Stock Purchase Agreement (the "Purchase Agreement"), by and between the Company and GCI Holdings (the "Global Cooling Divestiture"). Upon the execution of the Purchase Agreement, on April 17, 2024, Global Cooling business is presented in the  unaudited condensed financial statements as a discontinued operation for all periods presented. All amounts included in this earnings release relate to continuing operations unless otherwise noted.

BIOLIFE SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, amounts in thousands, except share and per share amounts)
	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands, except per share and share data)	2024		2023		2024		2023
Product revenue	$               21,310		$               22,786		$               41,167		$               46,307
Service revenue	4,427		4,175		9,513		8,197
Rental revenue	2,591		2,276		4,427		3,915
Total product, rental, and service revenue	28,328		29,237		55,107		58,419
Costs and operating expenses:
Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)	$               13,435		$               18,213		$               26,001		$               33,411
General and administrative	10,893		13,540		22,603		26,755
Sales and marketing	3,502		3,831		6,858		7,855
Research and development	2,382		3,793		4,776		7,033
Intangible asset amortization	910		1,406		1,824		2,823
Change in fair value of contingent consideration	—		(918)		—		(198)
Total operating expenses	31,122		39,865		62,062		77,679
Operating loss	(2,794)		(10,628)		(6,955)		(19,260)
Other (expense) income:
Change in fair value of equity investments	(4,074)		—		(4,074)		—
Gain on settlement of Global Cooling escrow	—		5,115		—		5,115
Interest expense, net	(361)		(387)		(529)		(767)
Other income	84		384		322		767
Total other (expense) income, net	(4,351)		5,112		(4,281)		5,115
Loss before income tax expense	(7,145)		(5,516)		(11,236)		(14,145)
Income tax expense	—		(2)		(121)		(94)
Net loss from continuing operations	$               (7,145)		$               (5,518)		$             (11,357)		$             (14,239)
Discontinued operations:
Loss from discontinued operations	(15,630)		(4,678)		(21,629)		(9,671)
Income tax expense	—		(3)		(10)		(3)
Loss from discontinued operations	$             (15,630)		$               (4,681)		$             (21,639)		$               (9,674)
Net loss	$             (22,775)		$             (10,199)		$             (32,996)		$             (23,913)
Loss from continuing operations, attributable to common shareholders:
Basic and Diluted	$               (7,145)		$               (5,518)		$             (11,357)		$             (14,239)
Loss from discontinued operations, attributable to common shareholders:
Basic and Diluted	$             (15,630)		$               (4,681)		$             (21,639)		$               (9,674)
Loss per share from continuing operations, attributable to common shareholders:
Basic and Diluted	$                 (0.16)		$                 (0.12)		$                 (0.25)		$                 (0.33)
Loss per share from discontinued operations, attributable to common shareholders:
Basic and Diluted	$                 (0.34)		$                 (0.11)		$                 (0.47)		$                 (0.22)
Net loss attributable to common shareholders:
Basic and Diluted	$             (22,775)		$             (10,199)		$             (32,996)		$             (23,913)
Net loss per share attributable to common shareholders:
Basic and Diluted	$                 (0.50)		$                 (0.23)		$                 (0.72)		$                 (0.55)
Weighted average shares used to compute loss per share attributable to common shareholders:
Basic and Diluted	46,004,037		43,441,219		45,718,232		43,235,558

 

BIOLIFE SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited, amounts in thousands)
	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2024		2023		2024		2023
Net loss	$       (22,775)		$       (10,199)		$       (32,996)		$       (23,913)
Other comprehensive income	11		35		(210)		180
Comprehensive loss	$       (22,764)		$       (10,164)		$       (33,206)		$       (23,733)

 

BIOLIFE SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION (Unaudited, amounts in thousands)
	June 30,		December 31,
(In thousands)	2024		2023
Cash, cash equivalents, and marketable securities	$          36,853		$          50,184
Working capital	57,381		78,426
Current assets	88,200		105,235
Current assets, discontinued operations	—		15,369
Current liabilities	30,819		29,382
Current liabilities, discontinued operations	—		12,796
Total assets	374,976		412,714
Long-term obligations, discontinued operations	—		1,027
Long-term obligations	22,715		31,846
Accumulated deficit(1)	(347,913)		(314,917)
Total shareholders' equity	321,442		337,663

(1) During the three months ended March 31, 2024, we determined that an immaterial error existed in our previously issued consolidated financial statements related to stock compensation expense on unvested shares of market-based awards of certain employees upon their termination. Our Accumulated deficit was impacted by the error by $1.6 million and was corrected within our Quarterly Report on Form 10-Q filed for the three months ended March 31, 2024.

 

BIOLIFE SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION (Unaudited, amounts in thousands)
	Six Months Ended June 30,
(In thousands)	2024		2023
Net cash used in (provided by) operating activities	$           1,984		$       (10,430)
Net cash provided by (used in) investing activities	(13,656)		12,218
Net cash provided by (used in) financing activities	(1,656)		142
Effects of currency translation	(65)		28
Net decrease (increase) in cash, cash equivalents, and restricted cash	$       (13,393)		$           1,958

As a result of the Company's divestiture of Global Cooling during the quarter, several financial metrics were re-forecasted to more closely align with continuing operations. During this process, several non-GAAP measures were adjusted, resulting in differences between previously reported non-GAAP results on a continuing operations basis. All adjusted items are designated with a (*) symbol.

BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP ADJUSTED GROSS MARGIN (Unaudited, amounts in thousands)
	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2024		2023		2024		2023
Total revenues	$     28,328		$     29,237		$     55,107		$     58,419
Cost of revenues	(13,435)		(18,213)		(26,001)		(33,411)
COGS intangible asset amortization	(577)		(733)		(1,159)		(1,466)
GROSS PROFIT	$     14,316		$     10,291		$     27,947		$     23,542
GROSS MARGIN	51 %		35 %		51 %		40 %
ADJUSTMENTS TO GROSS PROFIT:
Inventory reserve costs	—		2,185		—		2,185
Gain on disposal of assets*	(25)		—		(48)		—
Intangible asset amortization	577		733		1,159		1,466
ADJUSTED GROSS PROFIT	$     14,868		$     13,209		$     29,058		$     27,193
ADJUSTED GROSS MARGIN	52 %		45 %		53 %		47 %

 

BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP ADJUSTED OPERATING EXPENSES (Unaudited, amounts in thousands)
	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2024		2023		2024		2023
OPERATING EXPENSES FROM CONTINUING OPERATIONS	$        31,122		$        39,865		$        62,062		$        77,679
ADJUSTMENTS TO OPERATING EXPENSES FROM CONTINUING OPERATIONS:
Cost of product, rental, and service revenues	(13,435)		(18,213)		(26,001)		(33,411)
Acquisition costs	(153)		(2,143)		(390)		(2,976)
Intangible asset amortization	(910)		(1,406)		(1,824)		(2,823)
Gain (loss) on disposal of assets	25		(19)		100		(28)
Change in fair value of contingent consideration	—		918		—		198
Other income	300		—		300		—
ADJUSTED OPERATING EXPENSES FROM CONTINUING OPERATIONS	$        16,949		$        19,002		$        34,247		$        38,639

 

BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP OPERATING LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED OPERATING LOSS FROM CONTINUING OPERATIONS (Unaudited, amounts in thousands)
	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2024		2023		2024		2023
OPERATING LOSS FROM CONTINUING OPERATIONS	$        (2,794)		$       (10,628)		$        (6,955)		$       (19,260)
ADJUSTMENTS TO OPERATING LOSS FROM CONTINUING OPERATIONS
Inventory reserve costs	—		2,185		—		2,185
Acquisition costs	153		2,143		390		2,976
Intangible asset amortization	910		1,406		1,824		2,823
(Gain) loss on disposal of assets	(25)		19		(100)		28
Change in fair value of contingent consideration	—		(918)		—		(198)
Other income	(300)		—		(300)		—
ADJUSTED OPERATING LOSS FROM CONTINUING OPERATIONS	$        (2,056)		$        (5,793)		$        (5,141)		$       (11,446)

 

BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED NET LOSS FROM CONTINUING OPERATIONS (Unaudited, amounts in thousands)
	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2024		2023		2024		2023
NET LOSS FROM CONTINUING OPERATIONS	$        (7,145)		$        (5,518)		$       (11,357)		$       (14,239)
ADJUSTMENTS TO NET LOSS FROM CONTINUING OPERATIONS
Inventory reserve costs	—		2,185		—		2,185
Acquisition costs	153		2,143		390		2,976
Intangible asset amortization	910		1,406		1,824		2,823
(Gain) loss on disposal of assets	(25)		19		(100)		28
Change in fair value of equity investments	4,074		—		4,074		—
Change in fair value of contingent consideration	—		(918)		—		(198)
Other income	(300)		—		(300)		—
Income tax benefit	—		2		121		94
Gain on settlement of Global Cooling escrow	—		(5,115)		—		(5,115)
ADJUSTED NET LOSS FROM CONTINUING OPERATIONS	$        (2,333)		$        (5,796)		$        (5,348)		$       (11,446)

 

BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA FROM CONTINUING OPERATIONS (Unaudited, amounts in thousands)
	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2024		2023		2024		2023
NET LOSS FROM CONTINUING OPERATIONS	$     (7,145)		$     (5,518)		$    (11,357)		$    (14,239)
ADJUSTMENTS:
Interest expense, net	361		387		529		767
Accretion of available-for-sale investments*	(137)		(349)		(320)		(740)
Income tax benefit	—		2		121		94
Depreciation	1,464		1,731		2,898		5,045
Intangible asset amortization	910		1,406		1,824		2,823
EBITDA	$     (4,547)		$     (2,341)		$     (6,305)		$     (6,250)
OTHER ADJUSTMENTS:
Share-based compensation (non-cash)	5,461		5,732		10,699		11,732
Inventory reserve costs	—		2,185		—		2,185
Acquisition costs	153		2,143		390		2,976
(Gain) loss on disposal of assets	(25)		19		(100)		28
Change in fair value of equity investments	4,074		—		4,074		—
Change in fair value of contingent consideration	—		(918)		—		(198)
Other income	(300)		—		(300)		—
Gain on settlement of Global Cooling escrow	—		(5,115)		—		(5,115)
ADJUSTED EBITDA FROM CONTINUING OPERATIONS	$       4,816		$       1,705		$       8,458		$       5,358
% of Revenue	17 %		6 %		15 %		9 %

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-reports-second-quarter-2024-financial-results-302218340.html

SOURCE BioLife Solutions, Inc.

FAQ

What were BioLife Solutions' Q2 2024 financial results?

BioLife Solutions reported Q2 2024 revenue of $28.3 million, a GAAP gross margin of 51%, and a GAAP net loss of $7.1 million.

How did BioLife Solutions' Cell Processing revenue perform in Q2 2024?

Cell Processing revenue increased 11% sequentially to $18 million in Q2 2024.

What is BioLife Solutions' updated revenue guidance for 2024?

BioLife Solutions raised its full-year 2024 revenue guidance to $99 million to $101 million.

What was the adjusted EBITDA for BioLife Solutions in Q2 2024?

The adjusted EBITDA for BioLife Solutions in Q2 2024 was $4.8 million, 17% of revenue.

What was the net loss from continuing operations for BioLife Solutions in Q2 2024?

The GAAP net loss from continuing operations for BioLife Solutions in Q2 2024 was $7.1 million.